MOCON (MOCO) In Bearish Price Channel As Aegerion Pharmaceuticals (AEGR), Zep (ZEP), Concert Pharmaceuticals (CNCE)

MOCON, Technology, Zep
MOCON, Technology, Zep

Mocon Inc. (MOCO) reported that net income for the second quarter was $802,000, or $0.14 per share, evaluated to a net loss of $142,000 or $0.03 per share in the second quarter of 2012. The company-wide gross margin of 56 percent in the second quarter 2013 was slightly lower than the company’s historical levels, although was an improvement from the prior year second quarter margin of 48 percent. MOCON Inc. (MOCO), Scientific & Technical Instruments company, escalated 2.31% in last regular trading to $16.17. The stock is priced with the difference of 6.82% 200-day simple moving average and 2.50% 50-day moving average. At the closing bell, shares in MOCON Inc. recorded a trading volume of 7585. Its total outstanding shares are 5.65 million with the market capitalization of $91.33 million. MOCO showed 6.00% weekly performance.

Aegerion Pharmaceuticals Inc. (AEGR) declared a first quarter non-GAAP loss of $0.25 per share as soon as the bell Tuesday, contrasted to the loss of $0.51 a year ago. Aegerion Pharmaceuticals gapped open sharply lower Wednesday and is now down 9.82 at $34.34 on above average volume. The stock has shrunk to a new low for the year. Aegerion Pharmaceuticals, Inc. (AEGR), Biotechnology company, escalated 1.92% in last trading session and ended the day on $34.01. The stock is trading -66.33% below its 52-week high and 15.48% above its 52-week low. With 658348 of its shares exchanged hands during the day and 0.54 relative volume ratio, market capitalization of Aegerion Pharmaceuticals, Inc. moved to $1002.61 million. The float was recorded 27.44 million compared to 29.48 million outstanding shares. AEGR’s monthly performance is 2.59%. Trade experts think of it as ‘Buy’ stock.

Zep Inc (ZEP), a maker of cleaning and maintenance chemical products, Monday announced third-quarter net loss of $0.7 million or $0.03 per share, measured up with net income of $2.8 million or $0.12 per share last year. Results for the present quarter included $0.12 per share of integration and legal costs. Excluding items, adjusted earnings for the quarter were $2 million or $0.09 per share, evaluated with $3.2 million or $0.14 per share a year ago. Revenues for the quarter were lower at $157.8 million, evaluated with $163.4 million a year ago, due mainly to weather disruptions. Analysts polled by Thomson Reuters valued earnings of $0.08 per share on revenues of $159.1 million for the quarter. Zep, Inc. (ZEP), Cleaning Products, is currently trading at $17.72, which dropped -0.89%. The stock is trading -4.72% below its 50 days high and 5.98% above its 50 days low. ZEP’s price to free cash flow is 11.35%. Company is trading at a P/E multiple of 35.44x with 2.89% monthly volatility. The stock is having 6.10% return on equity and 2.10% return on assets. ZEP’s year to date performance is -1.88%. Investment experts consider it a ‘Hold’ stock.

Concert Pharmaceuticals reports 48 week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. Company points out CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation. Results suggest that CTP-499 has protective effects on kidney function in patients with type 2 diabetic kidney disease, a condition in which kidney function is progressively lost. Concert Pharmaceuticals, Inc. (CNCE), Biotechnology company, boosted 4.85% in last regular trading to $9.30. The stock is priced with the difference of -18.29% 200-day simple moving average and -2.59% 50-day moving average. CNCE has $166.47 million market capitalization. The stock recorded a trading volume of 126434 shares as compared to its average volume of 148.42 million shares. CNCE’s year to date performance is -34.41%. Trade experts think of it as ‘Buy’ stock.


Please enter your comment!
Please enter your name here